万基遗传 MYGN 深 沪
等待开盘 09-24 09:30:00 美东时间
4.01
-0.010
-0.25%
华盛通- 最 高4.225
- 今 开4.02
- 成交量 165.80万股
- 最 低 3.97
- 昨 收 4.02
- 总市值 3.84亿
- 52周最高 8.59
- 市盈率 静 --
- 换手率 1.73%
- 52周最低 2.74
- 委 比 -82.46%
- 总股本 9564.96万
- 历史最高 50.44
- 量 比 0.65
- 振 幅 6.34%
- 历史最低 2.74
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Myriad Genetics Announces Key Commercial Leadership Transition
Myriad Genetics ( ($MYGN) ) just unveiled an announcement. On September 16, 202...
09-16 22:57
Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
09-16 20:56
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026. Sikri previously served as Senior Vice President of Product and brings extensive experience in molecular diagnostics and oncology. Brian Donnelly, Chief Commercial Officer since May 2025, will depart on September 21. CEO Sam Raha expressed gratitude to Donnelly and confidence in Sikri's leadership to drive growth a...
09-16 12:00
Why RH Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of RH (NYSE:RH) rose sharply in pre-market trading after the company reported better-than-expected second-quarter earnings. RH reported quarterly earnings of $2.70 per share, which beat the Street estimate of $1.78 by 51.69%, per Benzinga Pro data. Quarterly revenue of $922.15 million missed ...
09-11 16:58
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.
09-10 02:05
Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted downbeat results for the second quarter. Cango reported quarterly losses of $1.99 per share which missed the...
09-01 20:02
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
<p>Myriad Genetics, Inc. will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on September 10, 2026. The presentation will be available via a live audio webcast on Myriad’s investor website. Myriad Genetics is a leading molecular diagnostic and precision medicine company focused on improving patient care through genetic insights. For more information, visit their website or contact investor and media relations.</p>
08-27 13:05
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5 to $3.
08-18 22:03
